Compare Charles River Laboratories Intl. Inc (CRL) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while ProShares UltraPro Short QQQ ETF trades at $38.87. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| CRL | SQQQ | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $233.60 | $97.60 |
52-Week Low | $145.57 | $36.31 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SQQQ (ProShares UltraPro Short QQQ ETF) trades at $39.95, up 5.74% ($2.17) in the last session. The ETF shows a neutral technical signal overall with bullish moving averages and neutral oscillators. Recent news highlights SQQQ's role as a tactical hedging tool against Nasdaq 100 declines, though long-term performance erosion due to daily -3x leverage remains a concern. Short interest increased 19.4% in March 2026, reflecting bearish sentiment toward tech.
Outlook: SQQQ is a high-risk, short-term instrument for hedging QQQ exposure, not a long-term investment. Opportunities exist for tactical investors during tech selloffs, but risks include volatility decay, timing challenges, and structural erosion. Investors should understand the leveraged ETF's mechanics and use it cautiously within a diversified strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
